skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Outcomes and Acute Toxicities of Proton Therapy for Pediatric Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

Abstract

Purpose: Atypical teratoid/rhabdoid tumor (AT/RT) of the central nervous system is a rare cancer primarily affecting children younger than 5 years old. Because patients are young and receive intensive chemotherapy, there is concern regarding late radiation toxicity, particularly as survival rates improve. Therefore, there is interest in using proton therapy to treat these tumors. This study was undertaken to investigate outcomes and acute toxicities associated with proton therapy for AT/RT. Methods and Materials: The records of 31 patients with AT/RT treated with proton radiation from October 2008 to August 2013 were reviewed. Demographics, treatment characteristics, and outcomes were recorded and analyzed. Results: Median age at diagnosis was 19 months (range, 4-55 months), with a median age at radiation start of 24 months (range, 6-62 months). Seventeen patients received local radiation with a median dose of 50.4 GyRBE (range, 9-54 GyRBE). Fourteen patients received craniospinal radiation; half received 24 GyRBE or less, and half received 30.6 GyRBE or more. For patients receiving craniospinal radiation, the median tumor dose was 54 GyRBE (range, 43.2-55.8 GyRBE). Twenty-seven patients (87%) completed the planned radiation. With median follow-up of 24 months for all patients (range, 3-53 months), median progression-free survival was 20.8 months and median overall survival was 34.3 months. Five patients (16%)more » developed clinical findings and imaging changes in the brainstem 1 to 4 months after radiation, consistent with radiation reaction; all cases resolved with steroids or bevacizumab. Conclusions: This is the largest report of children with AT/RT treated with proton therapy. Preliminary survival outcomes in this young pediatric population are encouraging compared to historic results, but further study is warranted.« less

Authors:
 [1];  [2]; ; ;  [3];  [1];  [4];  [3]
  1. Texas Children's Hematology and Oncology Centers, Department of Pediatrics, Baylor College of Medicine, Houston, Texas (United States)
  2. Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas (United States)
  3. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (United States)
  4. Department of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas (United States)
Publication Date:
OSTI Identifier:
22420507
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 90; Journal Issue: 5; Other Information: Copyright (c) 2014 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; BIOMEDICAL RADIOGRAPHY; CENTRAL NERVOUS SYSTEM; CHEMOTHERAPY; CHILDREN; COMPARATIVE EVALUATIONS; DIAGNOSIS; NEOPLASMS; PATIENTS; PEDIATRICS; PROTON BEAMS; RADIATION DOSES; RADIOTHERAPY; REVIEWS; STEROIDS; TOXICITY

Citation Formats

McGovern, Susan L., E-mail: slmcgove@mdanderson.org, Okcu, M. Fatih, Munsell, Mark F., Kumbalasseriyil, Nancy, Grosshans, David R., McAleer, Mary F., Chintagumpala, Murali, Khatua, Soumen, and Mahajan, Anita. Outcomes and Acute Toxicities of Proton Therapy for Pediatric Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System. United States: N. p., 2014. Web. doi:10.1016/J.IJROBP.2014.08.354.
McGovern, Susan L., E-mail: slmcgove@mdanderson.org, Okcu, M. Fatih, Munsell, Mark F., Kumbalasseriyil, Nancy, Grosshans, David R., McAleer, Mary F., Chintagumpala, Murali, Khatua, Soumen, & Mahajan, Anita. Outcomes and Acute Toxicities of Proton Therapy for Pediatric Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System. United States. https://doi.org/10.1016/J.IJROBP.2014.08.354
McGovern, Susan L., E-mail: slmcgove@mdanderson.org, Okcu, M. Fatih, Munsell, Mark F., Kumbalasseriyil, Nancy, Grosshans, David R., McAleer, Mary F., Chintagumpala, Murali, Khatua, Soumen, and Mahajan, Anita. 2014. "Outcomes and Acute Toxicities of Proton Therapy for Pediatric Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System". United States. https://doi.org/10.1016/J.IJROBP.2014.08.354.
@article{osti_22420507,
title = {Outcomes and Acute Toxicities of Proton Therapy for Pediatric Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System},
author = {McGovern, Susan L., E-mail: slmcgove@mdanderson.org and Okcu, M. Fatih and Munsell, Mark F. and Kumbalasseriyil, Nancy and Grosshans, David R. and McAleer, Mary F. and Chintagumpala, Murali and Khatua, Soumen and Mahajan, Anita},
abstractNote = {Purpose: Atypical teratoid/rhabdoid tumor (AT/RT) of the central nervous system is a rare cancer primarily affecting children younger than 5 years old. Because patients are young and receive intensive chemotherapy, there is concern regarding late radiation toxicity, particularly as survival rates improve. Therefore, there is interest in using proton therapy to treat these tumors. This study was undertaken to investigate outcomes and acute toxicities associated with proton therapy for AT/RT. Methods and Materials: The records of 31 patients with AT/RT treated with proton radiation from October 2008 to August 2013 were reviewed. Demographics, treatment characteristics, and outcomes were recorded and analyzed. Results: Median age at diagnosis was 19 months (range, 4-55 months), with a median age at radiation start of 24 months (range, 6-62 months). Seventeen patients received local radiation with a median dose of 50.4 GyRBE (range, 9-54 GyRBE). Fourteen patients received craniospinal radiation; half received 24 GyRBE or less, and half received 30.6 GyRBE or more. For patients receiving craniospinal radiation, the median tumor dose was 54 GyRBE (range, 43.2-55.8 GyRBE). Twenty-seven patients (87%) completed the planned radiation. With median follow-up of 24 months for all patients (range, 3-53 months), median progression-free survival was 20.8 months and median overall survival was 34.3 months. Five patients (16%) developed clinical findings and imaging changes in the brainstem 1 to 4 months after radiation, consistent with radiation reaction; all cases resolved with steroids or bevacizumab. Conclusions: This is the largest report of children with AT/RT treated with proton therapy. Preliminary survival outcomes in this young pediatric population are encouraging compared to historic results, but further study is warranted.},
doi = {10.1016/J.IJROBP.2014.08.354},
url = {https://www.osti.gov/biblio/22420507}, journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 5,
volume = 90,
place = {United States},
year = {Mon Dec 01 00:00:00 EST 2014},
month = {Mon Dec 01 00:00:00 EST 2014}
}